T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Recruiting · NCT06343311 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | B-cell neoplasm, B-cell non-Hodgkin lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma, primary central nervous system lymphoma, primary effusion lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT06343311 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Estrella Immunopharma, Inc. | 1 |
| Eureka Therapeutics Inc. | 4 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor Scott & White Research Institute, Texas Oncology | Dallas | United States | 1 |
| Intermountain Health, Canyons Region, LDS Hospital | Salt Lake City | United States | 1 |
| Oregon Health and Sciences University | Portland | United States | 20 |
| University Hospitals Seidman Cancer Center | Cleveland | United States | 10 |
| University of California, Davis | Sacramento | United States | 49 |